Please login to the form below

Not currently logged in
Email:
Password:

NICE issues final guidance on liraglutide

NICE publishes final guidance on the use of liraglutide (brand name Victoza) for people with type 2 diabetes in England, Wales and Northern Ireland

As part of its Single Technology Appraisal (STA) process to "fast track" appraisals of single technologies for single indications, the National Institute for Health and Clinical Excellence (NICE) has published final guidance on the use of liraglutide (brand name Victoza), a long-acting glucagon-like peptide-1 (GLP-1) analog, developed by Novo Nordisk, for patients with type 2 diabetes in England, Wales and Northern Ireland. 

NICE recommends once-daily liraglutide 1.2mg as a clinically- and cost-effective therapy in combination with two oral anti-diabetic tablets for the control of specific subgroups of people with type 2 diabetes detailed in the guidance.

It also recommends, irrespective of BMI, that liraglutide 1.2mg be used in combination with just one oral anti-diabetic tablet if other tablets are unsuitable in combination with current treatments or cannot be taken due to intolerances.

The new guidance instructs the National Health Service (NHS) to provide mandatory funding for liraglutide. Primary Care Trusts (PCTs) must find funding for the drug within three months for the appropriate patients as indicated by the guidance.

Commenting on the decision, Dr Marc Evans, consultant diabetologist at the Llandough Hospital in Cardiff, said: "Liraglutide represents a valuable option for patients with type 2 diabetes and their healthcare professionals. This is a significant step towards achieving health equality for people in England, Wales and Northern Ireland who qualify for treatment with liraglutide, which now requires mandatory funding from each PCT (Primary Care Trust)."

Liraglutide was approved by the European Medicines Agency (EMA) on July 3, 2009 and by the US Food and Drug Administration (FDA) for the treatment of type 2 diabetes in some adults on January 25, 2010.

27th October 2010

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics